Welcome to our dedicated page for Veradermics news (Ticker: MANE), a resource for investors and traders seeking the latest updates and insights on Veradermics stock.
Veradermics (MANE) news is driven mainly by clinical development updates for VDPHL01, the company’s investigational oral, non-hormonal, extended-release minoxidil tablet for pattern hair loss. Because Veradermics is a late-stage biopharmaceutical company, its most important updates often involve clinical trial results, study design, enrollment progress, safety observations, and data presentations in dermatology settings.
News about the company frequently focuses on male and female pattern hair loss studies, including Phase 2, Phase 2/3, and Phase 3 work. Updates may cover topline data, subgroup analyses, poster presentations, oral presentations, conference calls, and comparisons with existing minoxidil formulations when the company discloses those analyses. These items matter because VDPHL01 is the company’s lead program and defines much of the investment case for MANE stock.
Veradermics also generates financial and corporate news. Its releases and filings have covered quarterly financial results, clinical progress summaries, investor conference participation, public offerings, private placements, pre-funded warrants, and IPO registration materials. For a clinical-stage issuer, financing and cash-related disclosures are closely tied to the company’s ability to continue trial activity and prepare for potential regulatory and commercial steps.
Regular review of Veradermics news can help readers track how the company’s dermatology pipeline develops, how VDPHL01 data are reported, and how corporate filings align with public clinical updates.
Veradermics (MANE) will participate in three September 2026 healthcare investor conferences hosted by Wells Fargo, Citi, and Cantor.
Investor meetings are scheduled at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, in Boston. Company presentations will take place at Citi's 2026 Biopharma Back to School Conference on Wednesday, September 9, 2026 at 3:00 p.m. ET and at the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026 at 3:20 p.m. ET, both in New York. Live webcasts for the Citi and Cantor talks, plus 30‑day replays, will be available on Veradermics' investor relations website.
Veradermics (NYSE: MANE) reported second quarter 2026 results and progress on VDPHL01, its extended-release oral minoxidil for pattern hair loss in women and men. Cash, cash equivalents and marketable securities were $819.9 million as of June 30, 2026, which the company expects will fund operations into 2030, including multiple Phase 3 readouts and potential commercial launch, if approved.
According to Veradermics, open-label Phase 2 Study ‘207’ in female pattern hair loss showed mean hair count gains of 22.7 and 23.3 hairs/cm² at Month 6 with high responder rates and no treatment-related serious cardiac events. Enrollment was completed in the 556‑patient Phase 2/3 Study ‘306’ in women, with topline data expected in 1H27, while Phase 3 Study ‘304’ (men) and 12‑month data from Study ‘302’ (men) are anticipated in 2H26. Quarterly R&D expenses rose to $18.6 million and G&A to $10.9 million, driving a net loss of $23.5 million.
Veradermics (NYSE: MANE) announced new subgroup data from its randomized, double-blind, placebo-controlled Phase 2/3 Study ‘302’ evaluating VDPHL01, an extended-release oral minoxidil tablet, in over 500 males with mild-to-moderate pattern hair loss.
The analysis examines efficacy and safety by age (<40 vs ≥40 years). Results were presented in a poster on July 16, 2026, and will be highlighted in an oral session on July 17, 2026, at the 2026 AAD Innovation Academy in New York City. According to Veradermics, VDPHL01 is part of an extensive program targeting approval for both male and female pattern hair loss, with topline male Study ‘302’ results already reported, Phase 3 male Study ‘304’ fully enrolled with topline data expected in 2H 2026, and female trials ‘207’ and ‘306’ providing topline data timing through 1H 2027.
Veradermics (NYSE: MANE) reported positive topline results from Study ‘207’, an open-label Phase 2 trial of oral extended-release minoxidil candidate VDPHL01 in women with mild-to-moderate pattern hair loss. Participants received 4.5 mg once daily or twice daily for six months.
At Month 6, mean non-vellus target area hair count increased by 22.7 hairs/cm² (once daily) and 23.3 hairs/cm² (twice daily), with 88.9% and 90.0% of patients, respectively, reporting ‘improved’ or ‘much improved’ hair coverage on the AAIRS. Investigators graded 100% and 90% of participants as improved at Month 6. Fast onset was observed by Month 2. VDPHL01 was generally well tolerated, with no treatment-related SAEs and no cardiac AESIs. According to Veradermics, Study ‘207’ provides proof-of-concept on endpoints used in registration-directed Phase 2/3 Study ‘306’, with topline data expected in 1H 2027.
Veradermics (NYSE: MANE) announced it will host an investor conference call and live webcast on Wednesday, July 15, 2026 at 8:00 a.m. ET. The event will review results from the female treatment arms of Phase 2 open-label Study ‘207’ evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males and females with mild-to-moderate pattern hair loss.
The call, accompanying slides and a replay will be available via the Events page in the Investors section of Veradermics’ website.
Veradermics (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company developing therapeutics for pattern hair loss, will participate in two June investor conferences.
Management will present at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference, with live webcasts and 30-day replays on the investor relations site.
Veradermics (NYSE: MANE) will present topline results from the Phase 2/3 ‘302’ study of VDPHL01 at the 2026 World Congress for Hair Research on May 30, 2026. The trial evaluates an extended-release oral minoxidil tablet in over 500 males with pattern hair loss.
According to Veradermics, previously shared positive topline results from Part A may support VDPHL01 as a potential first FDA-approved oral pill for pattern hair loss in nearly 30 years.
Veradermics (NYSE: MANE) announced two E-poster presentations on its investigational extended-release oral minoxidil tablet VDPHL01 at the 2026 Music City SCALE Symposium in Nashville, running May 14–17, 2026.
Posters compare Phase 2 male AGA data for VDPHL01 with existing oral and topical minoxidil, using blinded dermatologist assessments and the AI-based Global HairMap™ (SOCAi) platform.
Veradermics (NYSE: MANE) reported Q1 2026 results and key clinical progress for VDPHL01, its oral treatment for pattern hair loss. Positive topline Phase 2/3 Study ‘302’ data in men showed robust hair growth and placebo-like safety. Enrollment milestones were reached across male and female trials.
The company raised about $766.8 million in 2026 through an upsized IPO and follow-on financing, with pro forma cash expected to fund operations into 2030. Q1 2026 R&D expenses were $20.9 million, G&A $8.9 million, and net loss $27.2 million.
Veradermics (NYSE:MANE) priced an upsized public offering of 3,843,790 common shares at $100.00 per share, raising approximately $384.4 million gross; offering expected to close on May 1, 2026. The company also agreed a private placement of 300,000 pre-funded warrants for about $30.0 million, closing subject to customary conditions.
An underwriter option of 576,568 additional shares is available for 30 days; several banks are acting as bookrunners and placement agents.